From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: OPTI

Search articles by EPIC code

OptiBiotix Health – after update from management, we continue to look for 100p+ for shareholders ahead

On developer of “compounds to tackle obesity, cardiovascular disease and diabetes”, OptiBiotix Health (OPTI) we’ve previously noted ‘some delays in delivery but a sales recovery Buy’ – including with “product launches by Apollo Pharmacies in India and restocking by some partners with sales normalising… as in previous years, there was no contribution in this period from licence or royalty payments which tend to be received in the second half”. We’ve since again spoken to CEO Steve O'Hara.


OptiBiotix Health – strategy and future plans update presentation and CEO chat

OptiBiotix Health (OPTI), a developer of “compounds to tackle obesity, cardiovascular disease and diabetes”, has recently provided an update presentation on its commercial strategy and future plans. At a current 19p, the shares are at least up from 16.5p lows last month but remain well down from above 30p as recently as August and 46p at the start of this year and we’ve spoken to CEO Steve O'Hara.


OptiBiotix Health – Apollo Hospitals and Pharmacies launch, Sales recovery Buy

Previously writing on OptiBiotix Health (OPTI), earlier this month we noted prior delays in delivery from larger deals but that orders are already coming through and being booked as second half sales. Now some clear evidence of this with an announcement that the company’s GoFigure meal replacement shakes and powdered beverage shots have now been officially launched by India's Apollo Hospitals & Pharmacies.


OptiBiotix Health – current trading disappointment, but highly favourable risk/reward here?

OptiBiotix Health (OPTI) has announced that it now expects half-year sales in its new structure to be materially lower than expected and, though it expects sales normalising in the second half and healthy growth next year, the current year is to now be “insufficient to make up the H1 deficit”. We profusely apologise for the short-term disappointment though, having spoken to the company, what to do now with the shares down at 20p to buy, a £17.6 million market cap?

Page 1 of 42 (411 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments